Congratulations to Prof. Vander Heiden, one of our amazing scientific advisors! ReviveMed, Inc.

Congrats to our CEO, Leila Pirhaji, for being selected as 20 Under 40: Young Shapers of the Future (Health and Medicine)!

Such a great work, summarizing the parameters needed for LC-MS signal detection! #datadriven #metabolomics

On my way to #neurips2022, excited to see talks and posters on AI in biology. DM me if you are working on GNN, deep unsurprised learning, or any AI/bio research.

We at ReviveMed, Inc. have tackled major data challenges in detecting #metabolite signals from mass spectrometry instruments. Our #AI now identifies high-quality signals at unprecedented levels, enabling the creation of large-scale #generative AI models previously impossible.

We have also expanded our work in #oncology, developing predictive tests to ensure that the right patients receive the appropriate treatment. Visit our updated website for more details, and stay tuned for exciting announcements! revivemed.io

I'm thrilled to share that our abstract, showcasing our AI-driven metabolomics platform, has been selected for presentation at the upcoming #ASCO conference in Chicago, May 31 - June 4. Join us at ASCO to learn how our platform is paving the way for advancing #precision medicine

Despite the transformative impact of cancer #immunotherapy, a significant number of patients do not respond to treatment. Our platform leverages #AI to analyze blood #metabolites to predict which patients will benefit from immunotherapy before treatment begins.

I'm excited to share that we will present at the upcoming Society for #Immunotherapy of #Cancer (SITC) conference Society for Immunotherapy of Cancer, showcasing our #AI-based #metabolomics platform and findings! 👇🧵 sitcancer.org/2024/abstracts…

PBRM1 is the second most mutated gene in clear-cell renal cell carcinoma; however, previous clinical trials have shown conflicting results regarding its association with responses to cancer immunotherapy. Our research has discovered that patients with PBRM1 mutations respond to

These findings help explain the inconsistent reports about PBRM1 mutations and ICI responses. They also suggest that metabolomics provides complementary information to genetics in predicting the outcomes of cancer immunotherapy.

I am excited to share that our abstract is now live on JITC! 🚀 We've demonstrated how #AI-based metabolomic analysis complements genetic stratification, shedding light on the hashtag#interplay between #genomic alterations and #metabolism in cancer immunotherapy response. While

I’m thrilled to announce that we’ve developed the first-in-class generative models for metabolomics powered by our innovative platform, mzLearn! 🚀 This is truly one of the most exciting times for AI research. As #generative models like DeepSeek and ChatGPT revolutionize various

MIT spinout ReviveMed uses AI to map the body’s metabolites — such as lipids, cholesterol, and sugars — and uncover hidden drivers of disease. These insights could help researchers determine how certain treatments work and who may benefit the most. mitsha.re/9OtX50V2JCv

Excited to share that Massachusetts Institute of Technology (MIT) News has featured our work at ReviveMed, Inc.! news.mit.edu/2025/mit-spino…

We’re pioneering #AI-driven #metabolomics to map the body’s metabolites and uncover hidden disease drivers, opening new frontiers in precision medicine. By leveraging #generative #AI to predict and interpret metabolic patterns, we’re unlocking deeper insights into complex

MIT spinout maps metabolites to uncover hidden disease drivers—reshaping diagnostics and treatment! 🧬 Read more: news.mit.edu/2025/mit-spino… #Biotech #MITStartups

mzLearn: Turning Metabolomics Data Swamps into Foundation-Model Fuel linkedin.com/pulse/mzlearn-…

Starting 2026 with exciting news! Our #mzLearn work is published in Nature Communications Chemistry 🎉 LC/MS #metabolomics has huge potential for disease research, but existing methods miss real signals and detect noise. mzLearn solves this with: 🧵 📄: nature.com/articles/s4200…